Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

NCT02207062 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131 ·Status: SUSPENDED ·Phase: PHASE1

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

NCT05950165 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT02950220 ·Status: COMPLETED ·Phase: PHASE1

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03369964 ·Status: WITHDRAWN ·Phase: PHASE1

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00550615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

NCT02309580 ·Status: COMPLETED ·Phase: PHASE1

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04510610 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00452127 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

NCT03126019 ·Status: COMPLETED ·Phase: PHASE2

Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00058019 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

NCT06392477 ·Status: RECRUITING ·Phase: PHASE1

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

NCT02082977 ·Status: TERMINATED ·Phase: PHASE1

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT03711578 ·Status: COMPLETED ·Phase: PHASE2

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

NCT01393106 ·Status: COMPLETED ·Phase: PHASE2

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

NCT00496431 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Patients Who Receive 131 I-MIBG

NCT04770831 ·Status: WITHDRAWN

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00655668 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT06021678 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

NCT00606645 ·Status: COMPLETED ·Phase: PHASE1